Business Context and Reporting Period
Company: Atai Beckley N.V. (formerly ATAI Life Sciences N.V.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: A clinical-stage biopharmaceutical company focused on developing psychedelic and non-psychedelic treatments for mental health disorders. The company recently completed a strategic combination with Beckley Psytech Limited (closed November 5, 2025) and is undergoing a redomiciliation to Delaware.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $0.75 million | $0.04 million | $3.02 million | $0.31 million |
| Net Loss (Attributable to Stockholders) | $(61.07) million | $(26.29) million | $(115.23) million | $(110.31) million |
| Net Loss Per Share (Basic & Diluted) | $(0.28) | $(0.16) | $(0.59) | $(0.69) |
| Operating Expenses | $29.19 million | $22.64 million | $77.10 million | $72.74 million |
| Cash and Cash Equivalents | $30.4 million (as of Sept 30, 2025) | |||
| Short-Term Securities | ||||
| Total Current Assets | $130.67 million | |||
| Total Current Liabilities | $16.54 million | |||
| Accumulated Deficit | $(815.44) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased significantly due to new research and development services revenue from the Nualtis subsidiary ($0.75 million in Q3 2025 vs. $0 in Q3 2024). License revenue from the Otsuka agreement ceased in Q1 2025 following termination.
- Net Loss Expansion: Net loss for Q3 2025 more than doubled compared to Q3 2024. This was primarily driven by a $32.6 million loss in "Change in fair value of assets and liabilities, net," largely attributed to the remeasurement of pre-funded warrant liabilities from recent PIPE financings and convertible note conversion options.
- Debt Extinguishment: The company fully repaid its $21.8 million Hercules Term Loan in May 2025, resulting in a $1.3 million loss on extinguishment of debt. There is no outstanding long-term debt as of September 30, 2025.
- Investment Activity: The company recognized a $17.6 million gain on its investment in COMPASS Pathways plc in Q3 2025. It also initiated a Bitcoin investment strategy, holding $11.4 million in digital assets as of period end.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects existing cash, cash equivalents, and short-term securities ($114.6 million combined) to fund operations for at least the next 12 months. Following the October 2025 public offering (subsequent event), the company estimates funding into 2029.
- Capital Raising: The company raised approximately $139.4 million in net proceeds from an October 2025 public offering. During the quarter, it also completed two PIPE financings (June and July 2025) raising approximately $79.9 million in gross proceeds.
- Strategic Combination: The acquisition of Beckley Psytech closed in November 2025. Risks include integration challenges, failure to realize anticipated synergies, and the uncertainty of clinical trial outcomes for the combined pipeline.
- Redomiciliation: The company is in the process of redomiciling from the Netherlands to Delaware. Risks include potential delays, creditor objections, or regulatory hurdles that could prevent the transaction.
- Development Risks: As a clinical-stage company, the business faces significant risks regarding the success of clinical trials (e.g., BPL-003, VLS-01, EMP-01), regulatory approvals, and the ability to commercialize products.
Investor Verification Checklist
- Warrant Liability Volatility: Verify the impact of the $57.4 million pre-funded warrant liability on future earnings, as changes in stock price directly affect net loss.
- Cash Runway: Confirm the burn rate post-October 2025 offering and the sufficiency of funds to reach Phase 3 trials for BPL-003 and VLS-01.
- Beckley Psytech Integration: Monitor the progress of the Beckley Psytech integration and the realization of cost synergies.
- Redomiciliation Status: Track the completion of the cross-border merger and Delaware redomiciliation to ensure no legal or tax impediments arise.
- Clinical Milestones: Watch for upcoming data readouts for EMP-01 (Q1 2026) and the FDA End-of-Phase 2 meeting for BPL-003.